Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Tumor and Lymph Node on Chip for cancer studies

Project description

Tumour–lymph node-on-chip platform for personalised cancer treatment

The lymphatic system is an integral part of the adaptive immune system, and in many cases, tumours use lymphatic vessels to spread and colonise downstream lymph nodes (LNs). The EU-funded Tumor-LN-oC project is funding a solution for a robust, automated tumour–lymph node-on-chip platform able to connect primary tumours and LN tissue obtained from the same cancer patient. The project will use advances in the fields of microfluidics, cell biology, cancer biology, physics and computer programming to study the interaction of primary tumours with LNs and offer personalised treatment based on molecular characterisation of metastasising cells.

Objective

The lymphatic system and lymph nodes (LNs) are an integral part of our adaptive immune system and many tumors exploit lymphatic vessels to spread and colonize downstream LNs. Tumor-LN-oC aims to offer a comprehensive solution for a robust, automated tumor-lymph node-on-chip platform that will connect primary surgically removed human tumors and LN tissue from the same cancer patient. This will allow us to study the interaction of primary tumors with lymph nodes, identify their chemical signature, and offer personalized treatment relying on molecular characterization of lymph node metastasizing cells. The project will significantly advance the fields of microfluidics, cell biology, cancer biology, physics, and computer programming and software development, by pursuing the following objectives: a) To introduce novel designs and develop robust, automated microfluidic chips optimized for tumor cell and LN culture enabling the study of their crosstalk, b) To integrate Quantum Cascade Laser based mid-IR spectroscopy for specific chemical signatures, c) To molecularly characterize both migrating tumor-derived cells attracted to the LN and the soluble signals driving migration, d) To demonstrate an advanced image analysis and signal processing platform using deep learning algorithms facilitated by a micro-optics module to monitor in real time the cells migration, e) To integrate all Tumor-LN-oC technologies in an automated platform prototype incorporating interfaces compatible with existing laboratory equipment. The Tumor-LN-oC platform, will be developed at TRL5 and will be validated using real patient samples. Regulatory pathways, standards and requirements compliance will be considered in order to facilitate exploitation and early market entry. The consortium encompasses key – industrial partners and experts in the aforementioned interdisciplinary fields and is expected to have substantial impact in EU’s economy and healthcare.

Keywords

Programme(s)

Topic(s)

Funding Scheme

RIA - Research and Innovation action

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-NMBP-TR-IND-2018-2020

See all projects funded under this call

Coordinator

EREVNITIKO PANEPISTIMIAKO INSTITOUTO SYSTIMATON EPIKOINONION KAI YPOLOGISTON
Net EU contribution
€ 745 000,00
Address
PATISION 42
106 82 ATHINA
Greece
Region
Αττική Aττική Κεντρικός Τομέας Αθηνών
Activity type
Research Organisations
Links
Total cost
No data

Participants (11)